Limits...
Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus

(a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.1976). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4562181&req=5

fig1: (a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.1976). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.

Mentions: The alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr) with no statistically significant changes (P = 0.1976, Figure 1(a)). We also showed UAlbCR of each participant before and after treatment by alogliptin in Figure 1(b).


Urinary Angiotensinogen Could Be a Prognostic Marker of Renoprotective Effects of Alogliptin in Patients with Type 2 Diabetes.

Mizushige T, Kobori H, Nishijima Y, Yano Y, Sakata K, Hayakawa M, Nishiyama A - J Diabetes Res (2015)

(a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.1976). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4562181&req=5

fig1: (a) Urinary concentrations of Alb normalized by urinary concentrations of creatinine (UAlbCR) before and 12-week after treatment with alogliptin. Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.1976). (b) UAlbCR of each participant before and 12-week after treatment with alogliptin.
Mentions: The alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr) with no statistically significant changes (P = 0.1976, Figure 1(a)). We also showed UAlbCR of each participant before and after treatment by alogliptin in Figure 1(b).

Bottom Line: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198).When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

View Article: PubMed Central - PubMed

Affiliation: Kagawa University School of Medicine, Kagawa 761-0793, Japan ; Jichi Medical University School of Medicine, Tochigi, Japan.

ABSTRACT

Background: The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D).

Methods: In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments. Urinary concentrations of albumin (Alb) and AGT, normalized by urinary concentrations of creatinine (Cr) (UAlbCR and UAGTCR, respectively), were measured before and after the 12-week alogliptin treatment.

Results: Alogliptin treatment tended to decrease UAlbCR (99.6 ± 26.8 versus 114.6 ± 36.0 mg/g Cr, P = 0.198). Based on % change in UAlbCR, patients were divided into two groups, responders (< -25%) and nonresponders (≥ -25%), and a logistic analysis of UAGTCR before treatment showed cutoff value of 20.8 µg/g Cr. When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L), Group H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).

Conclusion: Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.

No MeSH data available.


Related in: MedlinePlus